Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Eye Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Cleveland

Cleveland, Ohio, 44115, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

documented dry eye history
ocular symptoms
tear use
dry eye ocular signs

Exclusion criteria

Under 18

Treatment and study plan

Rimexolone

Drug

Primary outcomes

Corneal staining; dry eye sympton

Time frame: Immediate

Secondary outcomes

Corneal staining; dry eye sympton

Time frame: Prolonged

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: May 9, 2007
Registry last updated: Jun 5, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed